Bioengenieering platform developing localized biologics for immune-mediated disorders

NANO GROW

Nanobody-based therapies

Human and animal health · IP-intensive, capital-efficient B2B model — co-development and licensing with pharma.

€4.3M	5	10	7	€650K	24
SEED ROUND OPEN €3.0M COMMITTED €1.3M OPEN	ACTIVE COMMERCIAL AGREEMENTS 10+ LOIs	PROGRAMS RUNNING 5 AT ADVANCED PRECLINICAL STAGES	INTERNATIONAL PATENT FAMILIES	2026 REVENUE ·VS €140K IN 2025	PEOPLE · 4 COUNTRIES LABS IN SPAIN & URUGUAY

PROBLEM & MARKET OPPORTUNITY

Biologics are the gold standard for cancer and immune-mediated disorders (over €170B in annual sales) but their high costs and systemic administration limit accessibility. Systemic dosing causes adverse events in close to 50% of treated patients, only 1 in 4 eligible patients have access to biologics, and close to 80% of those with immune-mediated disease remain on corticosteroids of limited efficacy.
We **democratize that access**: nanobodies delivered locally — topically, orally, by inhalation or intratumorally — preserve the efficacy of a biologic while reducing systemic toxicity and costs.

THE PLATFORM — OUR CORE DIFFERENTIATOR

45 TARGETS · 34 DISCOVERY CAMPAIGNS

AI-accelerated discovery
Proprietary nanobody libraries plus a dry-lab engine, working closed-loop with the wet lab.

Localized by design
Topical, oral, inhaled or intratumoral delivery, with indication-specific formulation.

Modular, plug & play
Nanobodies fuse with third-party modalities — degraders, CAR-T, oncolytic vectors, ADCs.

PIPELINE

10 PROGRAMS RUNNING IN PARALLEL ON ONE PLATFORM

Nanogrow · Human Health — IBD, psoriasis, atopic dermatitis and allergic asthma
NanoVet · Animal Health — canine atopic dermatitis, feline chronic kidney disease, canine osteoarthritis and oncology.

Lead asset
Intratumoral immunocytokine, solid tumors

Abscopal effect on distant untreated tumours; intratumoral route reviewed as clinically feasible by thoracic surgeons at Clínica Universidad of Navarra.

IP: PCT WO2024/083988, exclusive licence. Published: Molecular Therapy, 2025.

~90%
antitumor effect in vivo

NO TOXICITY
in preclinical models

ROADMAP

MILESTONES OVER THE NEXT 3 YEARS

2026	2027	2028	2029	2030
Seed first close Humanized model · GMP batch	**Regulatory preclinical** Immunology PoCs · NanoVet spinoff	**IMPD/IND filed** Lead candidate licensing	**Phase I - Lead Candidate** First-in-human	**≥15 clients** Royalties · €17M+ 2026–2030

FOUNDERS

Nicolás Galmarini
CO-FOUNDER & CEO

Lucía Vanrell
CO-FOUNDER & CSO

Talk to the team — ngalmarini@nanogrowbiotech.com

BOARD

Stefan Oschmann (ex-CEO Merck) · **Jesús Hernández** (ex-VP Lilly) · **María Jesús Vicent** (Formulations Expert CURAPATH) · **Ignacio García Ribas** (ex-Sanofi & Lilly)· **Silvina García Rubio** (CMC and Drug Development at Formation Bio) · **Ferenc Scheeren** (LUMC Leader).